治疗下呼吸道感染3种方案的成本-效果分析  

Cost-effectiveness analysis of three therapeutic schemes in the treatment of lower respiratory tract infections

作　　者：杨雪梅[1] 吴庆欢[1] 梁丹[1] 肖锡州[1] 马凌燕[1] 郑翠[1] 

机构地区：[1]中山大学附属第二医院药学部,广东广州510120

出　　处：《中国医药导报》2008年第27期11-12,共2页China Medical Herald

摘　　要：目的:对治疗下呼吸道感染的3种用药方案进行临床疗效与成本-效果分析,从而寻找最佳治疗方案,指导临床更合理地选择和用药。方法:选择144例下呼吸道感染患者,随机分为A、B、C3组,每组48例,A组给予哌拉西林钠舒巴坦钠3.0g,qd;B组给予头孢呋辛钠1.5g,tid;C组给予头孢曲松钠1g,qd,均静脉滴注,疗程为7d。运用药物经济学的成本-效果分析方法进行药物经济学评价。结果:A、B、C组成本分别为1116.50、488.46及1300.88元(P<0.05);临床有效率分别为85.42%、79.17%及81.25%(P>0.05);成本-效果比分别为13.07、6.17、16.01。结论:从药物经济学的观点分析,B方案是治疗下呼吸道感染较佳的治疗方案。Objective： To analyze the cost-effectiveness of three therapeutic schemes in the treatment of lower respiratory tract infections, and seek for the best therapeutic scheme to guide a better choice and utilization of drug in clinic. Methods： 144 patients with lower respiratory tract infections were selected as the objectives, and then randomly divided into three groups： group A, B and C. Group A was treated with Piperacillin Sodium/Sulbactam Sodium for 3.0 g, qd; group B was treated with Cefuroxime Sodium for 1.5 g, rid; group C was treated with Ceftriaxone Sodium for 1 g, qd, all the drugs were used by intervenous drop infusion, the treatment course was 7 d. The cost-effectiveness analysis of pharmacoeco- nomics was employed to appraise the pharmacoeconomics effect. Results： The costs of the three therapeutic schemes were 1 116.50 yuan, 488.46 yuan and 1 300.88 yuan （P〈0.05） respectively; the effective rates were 85.42%, 79.17% and 81.25% （P〉0.05） respectively; the ratios of cost-effectiveness were 13.07, 6.17 and 16.01 respectively. Conclusion： Analyzed from the viewpoint of pharmacoeconomics, the B scheme is a better choice in the treatment of lower respiratory tract intections.

关 键 词：下呼吸道感染 治疗方案 成本-效果分析 

分 类 号：R56[医药卫生—呼吸系统]